Cargando…

Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis

Immune checkpoint inhibitors (ICIs) have become the standard of care for several cancers. However, ICI therapy has also been associated with various immune-related adverse events (irAEs). Clinical manifestations of immune-related colitis resemble those of inflammatory bowel diseases such as ulcerati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakai, Kazuko, Sakurai, Toshiharu, De Velasco, Marco A., Nagai, Tomoyuki, Chikugo, Takaaki, Ueshima, Kazuomi, Kura, Yurie, Takahama, Takayuki, Hayashi, Hidetoshi, Nakagawa, Kazuhiko, Kudo, Masatoshi, Nishio, Kazuto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578892/ https://www.ncbi.nlm.nih.gov/pubmed/34778085 http://dx.doi.org/10.3389/fonc.2021.763468

Ejemplares similares

Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis
por: Sakurai, Toshiharu, et al.
Publicado: (2021)

Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report
por: Komeda, Yoriaki, et al.
Publicado: (2020)

Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis
por: Sakurai, Toshiharu, et al.
Publicado: (2020)

Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model
por: Sakai, Kazuko, et al.
Publicado: (2021)

Deficiency of Gankyrin in the small intestine is associated with augmented colitis accompanied by altered bacterial composition of intestinal microbiota
por: Sakurai, Toshiharu, et al.
Publicado: (2020)

New Era for Next-Generation Sequencing in Japan
por: Takeda, Masayuki, et al.
Publicado: (2019)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3
por: Sakurai, Toshiharu, et al.
Publicado: (2017)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
por: Hirokawa, Esuteru, et al.
Publicado: (2021)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Performance of Idylla(™) RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer
por: Makutani, Yusuke, et al.
Publicado: (2022)

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter
por: SAKAI, KAZUKO, et al.
Publicado: (2015)

Cold-inducible RNA-binding protein promotes the development of liver cancer
por: Sakurai, Toshiharu, et al.
Publicado: (2015)

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
por: Kanemura, Hiroaki, et al.
Publicado: (2022)

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer
por: De Velasco, Marco A., et al.
Publicado: (2021)

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
por: Suda, Kenichi, et al.
Publicado: (2023)

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
por: De Velasco, Marco A., et al.
Publicado: (2016)

Toxic megacolon in Clostridium difficile colitis
por: Fukui, Sayato, et al.
Publicado: (2023)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
por: Kato, Ryoji, et al.
Publicado: (2020)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer
por: Togashi, Yosuke, et al.
Publicado: (2014)

Clinical and immune profiling for cancer of unknown primary site
por: Haratani, Koji, et al.
Publicado: (2019)

Removal of diminutive colorectal polyps: A prospective randomized clinical trial between cold snare polypectomy and hot forceps biopsy
por: Komeda, Yoriaki, et al.
Publicado: (2017)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
por: Togashi, Yosuke, et al.
Publicado: (2014)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
por: Nishio, Kazuto, et al.
Publicado: (2023)

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
por: KOGITA, AKIHIRO, et al.
Publicado: (2014)

Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series
por: Komeda, Yoriaki, et al.
Publicado: (2023)

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples
por: Ishii, Hidenobu, et al.
Publicado: (2015)

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
por: Ishii, Hidenobu, et al.
Publicado: (2020)

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
por: Arizumi, Tadaaki, et al.
Publicado: (2014)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
por: Sakai, Kazuko, et al.
Publicado: (2019)

The Efficacy of Sonazoid-enhanced Ultrasonography in Decision-making for Liver Abscess Treatment
por: Morita, Masahiro, et al.
Publicado: (2020)

Serum leucine‐rich alpha‐2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy‐naïve cases with ulcerative colitis
por: Kono, Masashi, et al.
Publicado: (2023)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v0m7in6r3dan28q88otdmtlmnb